Gujarat Themis Biosyn Q1 FY27: consolidated PAT up 22% YoY to ₹11.07 Cr as OPM expands 870bps
PAT +22.12% YoY · revenue +22.07% · margins expanding
₹43.79 Cr
+22.07% YoY
₹11.07 Cr
+22.12% YoY
25.2%
+0.1pp YoY
₹1.02
Gujarat Themis Biosyn's Q1 FY27 consolidated results (identical to standalone this quarter) show revenue of ₹43.79 Cr, up 22.1% YoY from ₹35.87 Cr, and PAT of ₹11.07 Cr, up 22.1% YoY from ₹9.06 Cr; EPS rose to ₹1.02 from ₹0.83. Sequentially the quarter was flat — revenue down 1.0% and PAT up 1.6% versus Q4 FY26. No exceptional items featured in either period. There is no analyst/street consensus coverage identifiable for this micro-cap (paid-up capital ₹10.90 Cr) and no formal management guidance on record, so the print cannot be benchmarked against external expectations; no separate management commentary or press release was available for this filing beyond the regulatory results statement.
Q1 FY-2027 vs prior quarters
Operating margin (EBITDA/revenue) expanded sharply to 47.5% from 38.8% a year ago (+870 bps), as revenue growth of 22.1% outran total expense growth of 19.7%. Much of the expense relief came from a bigger favourable swing in finished-goods/work-in-progress inventory build (₹-3.91 Cr this quarter versus just ₹-0.20 Cr YoY), which lowers the cost of goods recognised in the P&L, while employee costs rose faster than revenue at 51.7% YoY to ₹4.72 Cr. Net profit margin, however, was nearly flat at 25.2% versus 25.1% YoY — the operating-line gain was largely absorbed below the line by finance costs jumping to ₹1.79 Cr from just ₹0.04 Cr YoY and depreciation rising to ₹3.97 Cr from ₹2.03 Cr YoY, consistent with new capacity/assets coming onto the books and additional borrowing.
The stock went into the print at ₹375, down 0.2% over the past month of trading.
This is the company's first quarter reporting consolidated numbers, following incorporation of two wholly-owned subsidiaries, Themis Biosyn Japan and Themis Biosyn Ireland, both yet to commence operations and contributing nil revenue, profit and comprehensive income this quarter. Alongside the results, the company has called an EGM for August 22 to approve related-party transactions, and shareholding records this quarter show the promoter group releasing 25.45 lakh shares (1.51% of holding) from pledge while separately creating a fresh indirect encumbrance covering 47.02% of the promoter stake; promoter Sachin D Patel separately acquired 5.23 lakh shares.
W1
Whether the new finance-cost/depreciation run-rate (~₹1.79 Cr / ₹3.97 Cr per quarter) persists and continues to cap NPM despite OPM strength
W2
Outcome of the Aug 22 EGM on related-party transactions
W3
Whether Themis Biosyn Japan and Themis Biosyn Ireland begin contributing revenue/costs to consolidated numbers (both nil this quarter)